New research reveals distinct epidemiological trends in liver cancer across Mexico, with gender and regional variations ...
Zacks.com on MSN15h
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCCThe EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or ...
Hepatocellular carcinoma (HCC) represents about 80 to 90% of cases of primary liver cancer. On a global level, 905,700 new ...
Two new drugs to treat prostate and liver cancer have been given the green light for use by the NHS in Scotland. The Scottish ...
TWO new medicines have been approved to help treat prostate and liver cancer patients in Scotland. The Scottish Medicines ...
Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the European Commission ...
Plectin drives hepatocellular carcinoma progression and metastasis through cytoskeletal reorganization and oncogenic signaling, making it a promising therapeutic target for overcoming therapy ...
News-Medical.Net on MSN4d
Breakthrough study defines ideal interval for immunotherapy and liver transplantsHepatocellular carcinoma (HCC) represents about 80 to 90% of cases of primary liver cancer. On a global level, 905,700 new cases and 830,200 deaths were registered in 2020 according to the World ...
Hepatocellular carcinoma (HCC) represents about 80 to 90% of cases of primary liver cancer. On a global level, 905,700 new cases and 830,200 deaths were registered in 2020, according to the World ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback